Report of Foreign Issuer (6-k)
August 16 2019 - 11:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2019
Commission File Number 001-38512
Oncolytics
Biotech Inc.
(Translation of registrant’s name
into English)
Suite 210, 1167 Kensington Crescent
NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Note:
Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
o
Note:
Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
INCORPORATION BY REFERENCE
The Underwriting Agreement
dated August 14, 2019 included as Exhibit 99.1 of this Form 6-K and the Warrant Agent Agreement dated August 16, 2019
included as Exhibit 99.2 of this Form 6-K are incorporated by reference into the Registrant’s Registration Statement on Form F-10
(Commission File No. 333-224432).
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
|
|
99.1
|
|
Underwriting Agreement dated August 14, 2019
|
99.2
|
|
Warrant Agent Agreement dated August 16, 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Oncolytics Biotech Inc.
|
|
(Registrant)
|
|
|
|
By:
|
|
/s/
Kirk Look
|
|
|
|
|
|
|
|
Kirk Look
|
|
|
|
Chief Financial Officer
|
Date: August 16, 2019
|
|
|
|
Oncolytics Biotech (NASDAQ:ONCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncolytics Biotech (NASDAQ:ONCY)
Historical Stock Chart
From Apr 2023 to Apr 2024